BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16627760)

  • 1. Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.
    Flotho C; Coustan-Smith E; Pei D; Iwamoto S; Song G; Cheng C; Pui CH; Downing JR; Campana D
    Blood; 2006 Aug; 108(3):1050-7. PubMed ID: 16627760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CASP8AP2 is a promising prognostic indicator in pediatric acute lymphoblastic leukemia.
    Jiao Y; Cui L; Gao C; Li W; Zhao X; Liu S; Wu M; Deng G; Li Z
    Leuk Res; 2012 Jan; 36(1):67-71. PubMed ID: 21696825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low expressions of ARS2 and CASP8AP2 predict relapse and poor prognosis in pediatric acute lymphoblastic leukemia patients treated on China CCLG-ALL 2008 protocol.
    Cui L; Gao C; Zhang RD; Jiao Y; Li WJ; Zhao XX; Liu SG; Yue ZX; Zheng HY; Deng GR; Wu MY; Li ZG; Jia HT
    Leuk Res; 2015 Feb; 39(2):115-23. PubMed ID: 25530566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low expression of
    Cui L; Gao C; Wang CJ; Liu SG; Wu MY; Zhang RD; Li ZG
    Pediatr Hematol Oncol; 2020 Nov; 37(8):732-746. PubMed ID: 32804017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of CASP8AP2 and H2AFZ expression in survival and risk of relapse in children with acute lymphoblastic leukemia.
    Juárez-Velázquez R; Reyes-León A; Salas-Labadía C; Rivera-Luna R; Velasco-Hidalgo L; López-Hernández G; López-Santiago N; Paredes-Aguilera R; Domínguez-López A; Bernáldez R; Pérez-Vera P
    Leuk Lymphoma; 2014 Oct; 55(10):2305-11. PubMed ID: 24397596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypermethylation of two CpG sites upstream of CASP8AP2 promoter influences gene expression and treatment outcome in childhood acute lymphoblastic leukemia.
    Li ZG; Jiao Y; Li WJ; Deng GR; Cui L; Gao C; Zhao XX; Wu MY; Jia HT
    Leuk Res; 2013 Oct; 37(10):1287-93. PubMed ID: 23953914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia.
    Flotho C; Coustan-Smith E; Pei D; Cheng C; Song G; Pui CH; Downing JR; Campana D
    Blood; 2007 Aug; 110(4):1271-7. PubMed ID: 17456722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical significance of CASP8AP2 gene methylation in childhood acute lymphoblastic leukemia].
    Liu FF; Liu X; Wang KL; Li WJ; Deng GR; Gao C; Zhao XX; Wu MY; Cui L; Li ZG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):6-11. PubMed ID: 25687037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and prognostic significance of the apoptotic genes BCL2L13, Livin, and CASP8AP2 in childhood acute lymphoblastic leukemia.
    Yang YL; Lin SR; Chen JS; Lin SW; Yu SL; Chen HY; Yen CT; Lin CY; Lin JF; Lin KH; Jou ST; Hu CY; Chang SK; Lu MY; Chang HH; Chang WH; Lin KS; Lin DT
    Leuk Res; 2010 Jan; 34(1):18-23. PubMed ID: 20109966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
    Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
    Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
    Van der Velden VH; Corral L; Valsecchi MG; Jansen MW; De Lorenzo P; Cazzaniga G; Panzer-Grümayer ER; Schrappe M; Schrauder A; Meyer C; Marschalek R; Nigro LL; Metzler M; Basso G; Mann G; Den Boer ML; Biondi A; Pieters R; Van Dongen JJ;
    Leukemia; 2009 Jun; 23(6):1073-9. PubMed ID: 19212338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
    Gaipa G; Basso G; Biondi A; Campana D
    Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
    Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
    Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
    Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
    Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of immunophenotype, treatment response, and relapse in childhood acute lymphoblastic leukemia using DNA microarrays.
    Willenbrock H; Juncker AS; Schmiegelow K; Knudsen S; Ryder LP
    Leukemia; 2004 Jul; 18(7):1270-7. PubMed ID: 15152267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
    Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
    Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.
    Pui CH; Pei D; Raimondi SC; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Gruber TA; Leung WH; Yang JJ; Downing JR; Evans WE; Relling MV; Campana D
    Leukemia; 2017 Feb; 31(2):333-339. PubMed ID: 27560110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
    Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
    Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.